Pier Capital LLC Cuts Stake in Omnicell, Inc. (NASDAQ:OMCL)

Pier Capital LLC reduced its position in Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 27.9% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 96,863 shares of the company's stock after selling 37,511 shares during the period. Pier Capital LLC owned about 0.21% of Omnicell worth $4,312,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in OMCL. Smartleaf Asset Management LLC raised its stake in shares of Omnicell by 51.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 803 shares of the company's stock worth $35,000 after purchasing an additional 273 shares during the last quarter. Van ECK Associates Corp increased its holdings in Omnicell by 47.0% in the 4th quarter. Van ECK Associates Corp now owns 985 shares of the company's stock worth $44,000 after buying an additional 315 shares in the last quarter. First Horizon Advisors Inc. raised its position in Omnicell by 36.3% in the 4th quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company's stock worth $59,000 after buying an additional 355 shares during the last quarter. KBC Group NV boosted its holdings in shares of Omnicell by 60.8% during the 4th quarter. KBC Group NV now owns 2,057 shares of the company's stock valued at $92,000 after acquiring an additional 778 shares during the last quarter. Finally, AlphaQuest LLC grew its stake in shares of Omnicell by 307.8% in the fourth quarter. AlphaQuest LLC now owns 3,576 shares of the company's stock worth $159,000 after acquiring an additional 2,699 shares during the period. 97.70% of the stock is owned by institutional investors.

Remove Ads

Omnicell Stock Performance

Shares of OMCL stock traded down $0.34 during trading hours on Friday, reaching $35.01. 808,201 shares of the company traded hands, compared to its average volume of 518,911. The firm has a 50-day moving average price of $39.01 and a 200 day moving average price of $42.57. The company has a market cap of $1.64 billion, a P/E ratio of 129.67, a P/E/G ratio of 7.53 and a beta of 0.85. Omnicell, Inc. has a 12-month low of $25.12 and a 12-month high of $55.75. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 1.22.

Omnicell (NASDAQ:OMCL - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing analysts' consensus estimates of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. As a group, sell-side analysts predict that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

OMCL has been the topic of a number of research analyst reports. Wells Fargo & Company lowered their price objective on shares of Omnicell from $49.00 to $40.00 and set an "equal weight" rating on the stock in a research report on Monday, January 13th. Bank of America dropped their price target on Omnicell from $54.00 to $46.00 and set a "neutral" rating on the stock in a research note on Monday, January 6th. Benchmark reissued a "buy" rating and issued a $62.00 target price on shares of Omnicell in a report on Tuesday, February 4th. StockNews.com downgraded Omnicell from a "buy" rating to a "hold" rating in a research note on Monday, March 24th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Omnicell from $44.00 to $36.00 and set a "neutral" rating on the stock in a research note on Thursday, March 20th. Five analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat.com, Omnicell presently has an average rating of "Hold" and an average price target of $51.00.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.